Ian Estepan came to Sarepta in January 2015 as Head of Investor Relations. After more than 15 years of managing a portfolio on the buyside, Ian joined Sarepta for one reason: to have a direct and lasting impact on patients’ lives. He understands the importance of market access and the vast possibilities of science to ensure no patient is left behind in what is, as he believes, the golden age of 21st-century medicine.
In December 2020, Ian was appointed executive vice president and chief financial officer (CFO) of Sarepta. In this role, he oversees Finance, Corporate Strategy, Business Development, Strategic Alliances, Investor Relations and Corporate Affairs. Prior to his appointment as CFO, Ian served as Sarepta’s Chief of Staff, and oversaw the Investor Relations and Corporate Affairs functions. From 2017 to 2020, he led the development of Sarepta’s strategy and was a key architect in securing $2.5 billion in capital to support the Company’s growth. During his tenure, he has assumed increasing responsibilities, establishing the Corporate Strategy and Program Management functions, with an intense focus on advancing the interest of patients.
In a 2017 speech delivered during the opening ceremony of Sarepta’s Andover, Massachusetts facility, he called on the audience to appreciate the profound moment in time for biomedical innovation. Ian highlighted the importance of the 21st-Century Cures Act (of which Sarepta was part author) to ensure innovation continues for not only this generation of patients, but for those generations to come.
“Until my own son was born, witnessing a child with Duchenne get on therapy was the best day of my life. And I thought, imagine how I’ll feel if we can reach more kids. That’s why I ended up joining Sarepta.”
Ian began his career in finance as a healthcare sector analyst at Salomon Smith Barney in June 1999. He then spent two years at The Music Booth, LLP, a startup developing technology for advertising music on the internet. In August 2001, he moved on to the Spectra Financial Group, remaining there until joining Sarepta.
Ian holds a BA in psychology with a concentration in pre-medicine from Columbia University, where he graduated magna cum laude. He sits on Cellarity's Board of Directors and serves as executive chairman of AbBC Therapies. In 2022, Ian was recognized as a Boston Business Journal CFO of the Year.
What is Ian Michael Estepan's net worth?
The estimated net worth of Ian Michael Estepan is at least $4.04 million as of August 30th, 2024. Mr. Estepan owns 33,946 shares of Sarepta Therapeutics stock worth more than $4,038,556 as of December 21st. This net worth estimate does not reflect any other assets that Mr. Estepan may own. Additionally, Mr. Estepan receives an annual salary of $917,530.00 as EVP, Chief Financial Officer at Sarepta Therapeutics. Learn More about Ian Michael Estepan's net worth.
How old is Ian Michael Estepan?
Mr. Estepan is currently 48 years old. There are 4 older executives and no younger executives at Sarepta Therapeutics. The oldest executive at Sarepta Therapeutics is Mr. Douglas S. Ingram Esq., President, CEO & Director, who is 61 years old. Learn More on Ian Michael Estepan's age.
What is Ian Michael Estepan's salary?
As the EVP, Chief Financial Officer of Sarepta Therapeutics, Inc., Mr. Estepan earns $917,530.00 per year. There are 2 executives that earn more than Mr. Estepan. The highest earning executive at Sarepta Therapeutics is Mr. Douglas S. Ingram Esq., President, CEO & Director, who commands a salary of $1,620,000.00 per year. Learn More on Ian Michael Estepan's salary.
How do I contact Ian Michael Estepan?
Has Ian Michael Estepan been buying or selling shares of Sarepta Therapeutics?
Ian Michael Estepan has not been actively trading shares of Sarepta Therapeutics in the last ninety days. Most recently, Ian Michael Estepan sold 5,985 shares of the business's stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a transaction totalling $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares of the company's stock, valued at $4,662,822.56. Learn More on Ian Michael Estepan's trading history.
Who are Sarepta Therapeutics' active insiders?
Sarepta Therapeutics' insider roster includes Bilal Arif (EVP, Chief Technical Operations Officer), Richard Barry (Director), M. Behrens (Director), Kathryn Boor (Director), Joseph Bratica (Insider), Ryan Brown (EVP), Michael Chambers (Director), Ian Estepan (EVP, Chief Financial Officer), David Howton (EVP), Douglas Ingram (CEO), Stephen Mayo (Director), Dallan Murray (EVP, Chief Customer Officer), Louise Rodino-Klapac (Insider), and Hans Wigzell (Director). Learn More on Sarepta Therapeutics' active insiders.
Are insiders buying or selling shares of Sarepta Therapeutics?
In the last twelve months, Sarepta Therapeutics insiders bought shares 1 times. They purchased a total of 37,038 shares worth more than $4,955,684.40. In the last twelve months, insiders at the biotechnology company sold shares 11 times. They sold a total of 90,668 shares worth more than $13,164,125.22. The most recent insider tranaction occured on December, 12th when Director Hans Lennart Rudolf Wigzell sold 10,500 shares worth more than $1,310,820.00. Insiders at Sarepta Therapeutics own 7.7% of the company.
Learn More about insider trades at Sarepta Therapeutics. Information on this page was last updated on 12/12/2024.
